Theravance Biopharma (TBPH) Long-Term Deferred Tax (2014 - 2024)

Theravance Biopharma (TBPH) has 5 years of Long-Term Deferred Tax data on file, last reported at $2.4 million in Q4 2024.

• On a quarterly basis, Long-Term Deferred Tax fell 98.41% year-over-year to $2.4 million in Q4 2024; TTM through Dec 2024 was $2.4 million, a 98.41% decrease from a year earlier, with the FY2024 full-year figure at $2.4 million, down 98.41% from the prior year.
• Long-Term Deferred Tax for Q4 2024 stood at $2.4 million, down from $153.2 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for TBPH reached as high as $153.2 million in Q4 2023 and fell as low as $2.4 million in Q4 2024.
• Historically, Long-Term Deferred Tax has averaged $99.1 million across 3 years, with a median of $141.7 million in 2022.
• Across the five-year window, Long-Term Deferred Tax increased 8.15% in 2023 and slumped 98.41% in 2024, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $141.7 million in 2022, then advanced by 8.15% to $153.2 million in 2023, then slumped by 98.41% to $2.4 million in 2024.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $2.4 million in Q4 2024, $153.2 million in Q4 2023, and $141.7 million in Q4 2022.